Preparation of magnetically responsive albumin nanospheres andin vitrodrug release studies
Source abstract
Abstract
In this work, doxorubicin (DOX)-loaded magnetic albumin nanospheres were prepared using desolvation method in order to develop magnetically responsive nanocarrier system. Nanoparticles were characterized with zetasizer, SEM, AFM, XRD and magnetometer. In vitro DOX release was also investigated. It was found that nanoparticles had spherical shape with narrow size distributions and had magnetic responsiveness. In addition, slower drug release was observed with nanoparticulate system compared with free DOX. Moreover, the release rate should accelerate at target sites (cancer cells or tissue) where proteolytic enzymes are more abundant as known; therefore, magnetic albumin nanospheres can be effective potential DOX carrier with targeting ability.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · Characterization and Applications of Magnetic Nanoparticles · Iron oxide chemistry and applications
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (40)
Show source-provided references
1. Arruebo M · Nanotoday · 2007 · 2 · 2210.1016/S1748-0132(07)70084-1 ↗
2. Bradford MM · Anal Biochem · 1976 · 72 · 24810.1016/0003-2697(76)90527-3 ↗
3. Brannon-Peppas L · Adv Drug Deliver Rev · 2004 · 56 · 164910.1016/j.addr.2004.02.014 ↗
4. Chen D · J Biomed Res · 2010 · 24 · 2610.1016/S1674-8301(10)60005-X ↗
5. 10.1016/j.phrs.2010.01.01410.1016/j.phrs.2010.01.014 ↗
6. Danhier F · J Control Release · 2010 · 148 · 13510.1016/j.jconrel.2010.08.027 ↗
7. Dreis S · Int J Pharmaceut · 2007 · 341 · 20710.1016/j.ijpharm.2007.03.036 ↗
8. Dsouza AJM · J Pharm SCI-US · 2004 · 93 · 196210.1002/jps.20096 ↗
9. Dung DKT · J Phys Conf Ser · 2009 · 187 · 1
10. Easo SL · Carbohydr Polym · 2013 · 92 · 72610.1016/j.carbpol.2012.09.098 ↗
11. Elsadek B · J Control Release · 2012 · 157 · 410.1016/j.jconrel.2011.09.069 ↗
12. Elzoghby AO · J Control Release · 2012 · 157 · 16810.1016/j.jconrel.2011.07.031 ↗
13. Gaihre B · J Microencapsul · 2008 · 25 · 2110.1080/02652040701737697 ↗
14. Gaihre B · Int J Pharmaceut · 2009 · 365 · 18010.1016/j.ijpharm.2008.08.020 ↗
15. Gaumet M · Eur J Pharm Biopharm · 2008 · 69 · 110.1016/j.ejpb.2007.08.001 ↗
16. Jeong Y · Colloids Surf B Biointerfaces · 2010 · 79 · 14910.1016/j.colsurfb.2010.03.037 ↗
17. Jiang W · J Magn Magn Mater · 2004 · 283 · 21010.1016/j.jmmm.2004.05.022 ↗
18. Kairemo K · Curr Radiopharma · 2008 · 1 · 3010.2174/1874471010801010030 ↗
19. Kratz F · J Control Release · 2008 · 132 · 17110.1016/j.jconrel.2008.05.010 ↗
20. Kumar C · 2006 · 2 · 145
21. Langer K · Int J Pharmaceut · 2003 · 257 · 16910.1016/S0378-5173(03)00134-0 ↗
22. Li FQ · Int J Pharmaceut · 2008 · 349 · 27410.1016/j.ijpharm.2007.08.001 ↗
23. Li JM · Acta Pharmacol Sin · 2009 · 30 · 133710.1038/aps.2009.125 ↗
24. 10.1016/S0928-0987(00)00169-X10.1016/S0928-0987(00)00169-X ↗
25. Min K · Biomaterials · 2011 · 32 · 212410.1016/j.biomaterials.2010.11.035 ↗
26. 10.1016/S1535-6108(03)00276-910.1016/S1535-6108(03)00276-9 ↗
27. Qu X · J Drug Target · 2010 · 18 · 35110.3109/10611860903450049 ↗
28. Reddy LH · J Drug Target · 2004 · 12 · 44310.1080/10611860400011406 ↗
29. Shen Z · Eur J Pharmaceut Sci · 2008 · 35 · 27110.1016/j.ejps.2008.07.006 ↗
30. 10.1016/j.phrs.2010.10.01210.1016/j.phrs.2010.10.012 ↗
31. Shen Z · Pharmacol Res · 2011 · 64 · 41010.1016/j.phrs.2011.06.015 ↗
32. Siegel R · CA Cancer J Clin · 2012 · 62 · 1010.3322/caac.20138 ↗
33. Singh R · Exp Mol Pathol · 2009 · 86 · 21510.1016/j.yexmp.2008.12.004 ↗
34. Sun J · J Biomed Mater Res A · 2006 · 80 · 333
35. 10.1208/pt06011210.1208/pt060112 ↗
36. Wagner S · Biomaterials · 2010 · 31 · 238810.1016/j.biomaterials.2009.11.093 ↗
37. Widder KJ · Cancer Res · 1980 · 40 · 3512
38. Yang X · Polymer · 2008 · 49 · 347710.1016/j.polymer.2008.06.005 ↗
39. Zhang J · Acta Biomaterialia · 2007 · 3 · 83810.1016/j.actbio.2007.05.011 ↗
40. Zhao D · Int J Nanomed · 2010 · 5 · 669